AbbVie Inc. (ABBV)
| Market Cap | 331.41B |
| Revenue (ttm) | 57.37B |
| Net Income (ttm) | 4.16B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.34 |
| PE Ratio | 80.18 |
| Forward PE | 16.69 |
| Dividend | $6.56 (3.50%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 2,093,091 |
| Open | 187.50 |
| Previous Close | 187.34 |
| Day's Range | 185.05 - 188.60 |
| 52-Week Range | 162.16 - 218.66 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 211.55 (+12.76%) |
| Earnings Date | Jul 24, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $211.55, which is an increase of 12.76% from the latest price.
News
June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, a...
Bert's May 2025 Dividend Income Summary
Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for...
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three ...
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025.
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, r...
Final Trades: JPMorgan, Meta, Abbvie and Gap
The Investment Committee give you their top stocks to watch for the second half.
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) ann...
When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lowe...
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies
NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced a str...
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
- Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lun...
69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs
Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten...
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
Is It Time To Buy AbbVie Stock At $180?
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This prot...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV du...
Jim Cramer talks good companies getting pummeled by rising interest rates
'Mad Money' host Jim Cramer talks opportunity stocks as rising interest rates weigh on some equities.
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t...
AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ET Company Participants Jeff Stewart - EVP and Chief Commercialization Officer Roopal Thakkar - EVP and R&D, Ch...
Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's
The Investment Committee debate the latest Calls of the Day.
US FDA approves AbbVie's drug for a type of lung cancer
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment...
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapi...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline
OXFORD, England--(BUSINESS WIRE)-- #biotech--Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics.